VGVirginie Grouthier

Virginie Grouthier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Virginie Grouthier has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Anne Bachelot

    Department of Endocrinology and Reproductive Medicine and Centre de Référence des Maladies Endocriniennes Rares de la Croissance et du Développement, Centre de Référence des Pathologies Gynécologiques Rares, AP‐HP, IE3M Hôpital Pitié‐Salpêtrière Paris France

    1 shared publication
  • Aude Brac de la Perrière

    Service d’Endocrinologie, de Diabétologie Et Des Maladies Métaboliques A, Hospices Civiles de Lyon, Lyon, France

    1 shared publication
  • Camille Verebi

    Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, Equipe Gorwood/Ramoz Paris France

    1 shared publication
  • Christian Funck-Brentano

    AP-HP, Sorbonne Université, Pitié-Salpêtrière Hospital, Department of Pharmacology and Clinical Investigation Centre, Paris 75013, France; INSERM, CIC-1901 and UMR-S 1166, Sorbonne Université, Faculty of Medicine, Paris, France

    1 shared publication
  • Corinne Fouveaut

    Service de Médecine Génomique Des Maladies de Système Et d’Organe, Hôpital Cochin, APHP, Centre Université de Paris Cité, Paris, France

    1 shared publication
  • Céline Gache

    1 shared publication

Latest Publications

  • NOBOX gene variants in premature ovarian insufficiency: ethnicity-dependent insights

    by Pénélope Jordan, Camille Verebi, Sandrine Perol, Sarah Grotto, Corinne Fouveaut, Sophie Christin-Maitre, Aude Brac de la Perrière, Virginie Grouthier, Sophie Jonard-Catteau, Philippe Touraine, et al.

    Purpose Premature ovarian insufficiency (POI) affects approximately 1% of women before the age of 40. Genetic contribution is a significant component of POI. The NOBOX gene was considered one of the major genetic causes of POI. However, the pathogenicity and the penetrance of NOBOX variants remain unclear. Methods We studied the whole coding region of the NOBOX gene by next generation sequencing in a cohort of 810 patients with POI, and we compared the frequency of each identified NOBOX variant to the general population taking into account the ethnicity of each individual. Results Screening of the whole coding region of the NOBOX gene allowed us to identify 35 different variants, including 5 loss-of-function variants. In total, 171 patients with POI (25%) carried out at least one NOBOX variant. Regarding missense variants, we observed a significant overrepresentation of the most frequent ones in our 810 POI patients as compared to the general, except for p.(Arg117Trp). However, taking into account the ethnic origin of the individuals, we observed no significant OR difference for p.(Arg44Leu) and p.(Arg117Trp) in African subgroup and for p.(Asp452Asn) in European subgroup. Conclusion This population study suggests that the p.(Arg44Leu) variant could be considered benign variant and that the p.(Asp452Asn) and p.(Arg117Trp) variants could be considered moderate risk pathogenic variants with probably partial and very low penetrance and/or expressivity. In contrast, p.(Gly91Trp) and p.(Gly152Arg) variants could be considered pathogenic variants with a moderate functional impact.


  • Open Access

    Sexual Dimorphisms, Anti-Hormonal Therapy and Cardiac Arrhythmias

    by Virginie Grouthier, Melissa Y. Y. Moey, Estelle Gandjbakhch, Xavier Waintraub, Christian Funck-Brentano, Anne Bachelot, Joe-Elie Salem

    Significant variations from the normal QT interval range of 350 to 450 milliseconds (ms) in men and 360 to 460 ms in women increase the risk for ventricular arrhythmias. This difference in the QT interval between men and women has led to the understanding of the influence of sex hormones on the role of gender-specific channelopathies and development of ventricular arrhythmias. The QT interval, which represents the duration of ventricular repolarization of the heart, can be affected by androgen levels, resulting in a sex-specific predilection for acquired and inherited channelopathies such as acquired long QT syndrome in women and Brugada syndrome and early repolarization syndrome in men. Manipulation of the homeostasis of these sex hormones as either hormonal therapy for certain cancers, recreational therapy or family planning and in transgender treatment has also been shown to affect QT interval duration and increase the risk for ventricular arrhythmias. In this review, we highlight the effects of endogenous and exogenous sex hormones in the physiological and pathological states on QTc variation and predisposition to gender-specific pro-arrhythmias.